Safety and efficacy of vardenafil in patients with erectile dysfunction: Result of a bridging study in Japan

International Journal of Urology

Volumn 11, Issue 7, 2004, Pages 515-524

  Nagao, Koichi ^a   Ishii, Nobuhisa ^a   Kamidono, Sadao ^b   Osada, Takao ^c  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Erectile dysfunction; Phosphodiesterase type 5 inhibitor; Vardenafil

Indexed keywords

PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; VARDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLATULENCE; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SEXUAL FUNCTION; SIDE EFFECT;

ADULT; AGED; DOUBLE-BLIND METHOD; HUMANS; IMIDAZOLES; IMPOTENCE; JAPAN; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES; SULFONES; TRIAZINES;

EID: 4043055144     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00833.x     Document Type: Article

References (23)

1. NIH Consensus Development Panel on Impotence. NIH Consensus Conference: impotence. JAMA 1993; 270: 83-90.
2. Shirai M, Takanami M, Tanaka T. A stochastic survey of impotence population in Japan. Impotence 1987; 2: 67-93.
3. Shirai M. Trend of erectile dysfunction patients in Japan. Modern Physician 1999; 19: 1081-3.
4. Levine LA. Diagnosis and treatment of erectile dysfunction. Am. J. Med. 2000; 109 (Suppl. 1): 3-12.
5. Feldman HA, Johannes CB, Derby CA et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev. Med. 2000; 30: 328-38.
6. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537-44.
7. Nagao K. Erectile dysfunction. Jpn Clin. Endocrinol. 2002; 50: 51-8.
8. Bischoff E, Niewoehner U, Haning H, Es Sayed M, Schenke T, Schlemmer KH. Vardenafil a potent and selective inhibitor of phosphodiesterase type 5 increase cGMP in rabbit corpus cavernosum. Int. J. Impot. Res. 2001; 13 (Suppl. 1): S25.
9. Bischoff E, Niewoehner U, Haning H, Es Sayed M, Schenke T, Schlemmer KH. The oral efficacy of vardenafil hydrochloride in a conscious rabbit model. J. Urol. 2001; 165: 1316-28.
10. Bischoff E, Schneider K. A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection. Int. J. Impot. Res. 2001; 13: 230-5.
11. Pryor J. Vardenafil: update on clinical experience. Int. J. Impot. Res. 2002; 14 (Suppl. 1): S65-S69.
12. Porst H, Rosen R, Padma-Nathan H et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int. J. Impot. Res. 2001; 13: 192-9.
13. Goldfischer E, Eardley I, Segerson T. Vardenafil improves erectile function in men with significant comorbidities associated with erectile dysfunction (ED) (Abstract). J. Urol. 2002; 167 (Suppl. 4): 178.
14. Donatucci C, Eardley I, McVary KT, Thibonnier M. Vardenafil improves erectile function regardless of etiology or baseline severity in men with erectile dysfunction (Abstract). J. Urol. 2002; 167 (Suppl. 4): 178.
15. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26 (3): 777-83.
16. Brock G, Taylor T, Seger M. Efficacy and tolerability of vardenafil in males with erectile dysfunction following radical prostatectomy. Eur. Urol. 2002; 1 (Suppl. 1): 152.
17. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
18. Fugl-Meyer AR, Lodnert G, Branholm IB, Fugl-Meyer KS. On life satisfaction in male erectile dysfunction. Int. J. Impot. Res. 1997; 9: 141-8.
19. Tan HM, Moh CL, Mendoza JB et al. Asian sildenafil efficacy and safety study (ASSESS-1): a double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. Urology 2000; 56: 635-40.
20. Lim PH, Ng FC, Cheng CW et al. Clinical safety profile of sildenafil in Singaporean men with erectile dysfunction: pre-marketing experience (ASSESS-I evaluation). J. Int. Med. Res. 2002; 30: 137-43.
21. Goldstein I, Young J, Segerson T, Thibonnier M. Influence of HbA1c on the efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with diabetes (Abstract). Diabetes 2002; 51 (Suppl. 2): A98.
22. Goldstein I, Young J, Segerson T, Thibonnier M. Long-term efficacy and safety of diabetic men with erectile dysfunction (Abstract). Diabetes 2002; 51 (Suppl. 2): A98.
23. Fink HA, MacDonald R, Rutks IR, Nelson DB, Wilt TJ. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch. Intern. Med. 2002; 162: 1349-60.